Form 4: Vir Biotechnology EVP Vanina de Verneuil Reports Stock Transactions

Vanina de Verneuil, EVP and General Counsel of Vir Biotechnology, reports acquisition and disposal of company stock and stock options.

Summary

• Vanina de Verneuil, EVP and General Counsel of Vir Biotechnology, filed a Form 4 detailing changes in beneficial ownership.
• On February 22, 2025, she acquired 35,000 shares of common stock at $0, and a stock option (Right to Buy) for 70,000 shares at $9.57.
• On February 24, 2025, she disposed of 5,140 shares of common stock at $9.4534 per share.
• Following these transactions, she beneficially owns 86,833 shares of common stock and holds options for 70,000 shares.
• The sale of shares on February 24, 2025, was to cover tax obligations related to the vesting of restricted stock units.
• The stock options vest over time, with 25% vesting on February 22, 2026, and the remainder in 36 equal monthly installments.

Sentiment

Score: 6

Explanation: Neutral sentiment. The transactions are a mix of acquisition and disposal, with the disposal explained as covering tax obligations. The acquisition of shares and options is a slightly positive signal.

Positives

• Acquisition of 35,000 shares indicates confidence in the company.
• Grant of stock options incentivizes long-term performance.

Negatives

• Sale of 5,140 shares, although for tax obligations, could be perceived negatively.

Risks

• Executive stock sales, even for tax purposes, can sometimes create short-term market uncertainty.

Future Outlook

The vesting schedule of the stock options suggests a long-term commitment from the executive.

Industry Context

Executive stock transactions are common and closely monitored in the biotechnology industry. Acquisitions can signal confidence, while sales are often scrutinized for potential insider information or lack of faith in the company's future.

Comparison to Industry Standards

• Executive compensation packages in biotech often include stock options and restricted stock units to align management interests with shareholder value, similar to companies like Gilead Sciences and Amgen.
• The vesting schedule of these options is fairly standard, with a multi-year vesting period to encourage long-term commitment, comparable to practices at Regeneron and Biogen.

Stakeholder Impact

• The transactions could have a minor impact on shareholder sentiment, depending on how they are interpreted.

Key Dates